At the news
? BULLISHIMPACT 4/10 CLUSTER filed Nov 18, 2026 at 17:21 ET
Two insiders at CorMedix, including CEO Joseph Todisco and Director Myron Kaplan, made open-market purchases totaling $513K over a 7-day window. The CEO's $391K buy and the Director's $122K buy follow the company's Q3 2026 earnings release (revenue beat, narrowed EBITDA guidance) and the announced Heron Therapeutics asset acquisition, signaling insider confidence in the post-earnings outlook and growth strategy.
- CEO Joseph Todisco purchased 80,000 shares at $4.89 for $391,200 on 2026-11-13 (open-market, no 10b5-1 plan)
- Director Myron Kaplan purchased 25,000 shares at $4.88 for $122,000 on 2026-11-16 (open-market, no 10b5-1 plan)
- Total insider purchases of $513,200 represent 0.13% of the $383M market cap
- Purchases occurred 1-4 days after Q3 2026 earnings (Nov 12) which beat revenue consensus ($54.5M vs $51.2M) and narrowed adjusted EBITDA guidance
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access